Generic Name and Formulations:
Dexamethasone 0.7mg in the Novadur delivery system; intravitreal implant; preservative-free.
Indications for OZURDEX:
Macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). Non-infectious uveitis affecting the posterior segment of the eye. Diabetic macular edema.
For ophthalmic intravitreal injection only. One implant in each affected eye(s).
Ocular or periocular infections. Glaucoma (cup to disc ratio >0.8). Torn or ruptured posterior lens capsule.
Monitor for intravitreal injection-related effects (eg, endophthalmitis, eye inflammation, increased intraocular pressure, retinal detachments) following the injection. Risk of potential steroid-related effects (eg, posterior subcapsular cataracts, glaucoma, secondary ocular infections). History of ocular herpes simplex: not recommended. Risk of implant migration to anterior chamber if posterior lens capsule is not intact. Pregnancy. Nursing mothers.
Increased intraocular pressure, conjunctival hemorrhage, eye pain, conjunctival hyperemia, ocular hypertension, cataracts.
Single-use intravitreal implant—1 (w. applicator)
Neurology Advisor Articles
- Deep Brain Stimulation Improves Parkinson Disease in Older Adults
- Optimizing Treatment for Patients With Chronic Sciatica: Gabapentin vs Pregabalin
- Tiglutik Now Available for the Treatment of Amyotrophic Lateral Sclerosis
- Modifiable CV Risk Factors Within Healthy Range Indicative of CV Morphology, White Matter Lesions
- A New Look at Demyelination and White Matter Density in Multiple Sclerosis